- theory and concepts
- decision theory
- decision psychology
- probability/bayes
- preferences/values
- health outcomes
- calibration/validation
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- chronic disease/risk
- business/industry
- health/medicine
Resources Repository
-
ArticlePublication 2017Simulation of Growth Trajectories of Childhood Obesity into Adulthood
The authors developed a simulation model to estimate the risk of adult obesity at the age …
The authors developed a simulation model to estimate the risk of adult obesity at the age of 35 years for the current population of children in the United States. They used pooled height and weight data from five nationally representative longitudinal studies totaling 176,720 observations from 41,567 children and adults to simulate growth trajectories across the life course adjusted for secular trends. Using 1,000 virtual populations of 1 million children through the age of 19 years, representative of the…
Health Outcomes | Health/Medicine | Chronic Disease/Risk | Microsimulation | Child/Nutrition | North America -
ArticlePublication 2017Cost-Effectiveness of Screening for Hypertension and Counseling for Prevention
This article aimed to compare the health and economic impact of 3 services recommended by …
This article aimed to compare the health and economic impact of 3 services recommended by the US Preventive Services Task Force for the primary prevention of cardiovascular disease (CVD): (1) aspirin counseling for the primary prevention of CVD and colorectal cancer, (2) screening and treatment for lipid disorders (usually high cholesterol), and (3) screening and treatment for hypertension. A microsimulation model was used to compare lifetime outcomes from the societal perspective for a US-representative birth…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Microsimulation | Policy/Regulation | Clinical Care | North America -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Test Performance | State-Transition | Microsimulation | Infectious Diseases | Health Systems | Economics/Finance | Global | North America -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Priority Setting/Ethics | Costing Methods | Infectious Diseases | Health Systems | Economics/Finance | Government/Law | Science/Technology | Global -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Benefit-Cost Analysis | Health/Medicine | Chronic Disease/Risk | Costing Methods | Policy/Regulation | Government/Law | North America -
ArticlePublication 2017OOP Expenditures for Cardiovascular Disease
This article, published in BMJ Global Health, aims to estimate the magnitude and intensity of …
This article, published in BMJ Global Health, aims to estimate the magnitude and intensity of catastrophic health expenditure (CHE) and factors associated with CHE for the prevention and treatment of cardiovascular disease in hospitals in Addis Ababa. Seeking prevention and treatment services for cardiovascular disease in Addis Ababa was found to pose substantial financial burden on households, affecting the poorest and those who reside outside Addis Ababa more. Economic and geographic inequalities should therefore be…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Health Systems | Sub-Saharan Africa -
ArticlePublication 2017Cost-Effectiveness of Subsidizing Fruit and Vegetable through SNAP
A diet high in fruits and vegetables is associated with reduced risk of chronic disease …
A diet high in fruits and vegetables is associated with reduced risk of chronic disease - to incentivize consumption among low-income households one proposal is to make them more affordable through the Supplemental Nutrition Assistance Program (SNAP). This cost effectiveness analysis adopts a societal perspective to estimate the value of subsidizing fruit and vegetable (FV) purchases among the one in seven Americans who participate in SNAP. A stochastic microsimulation model of obesity, type 2 diabetes, myocardial infarction,…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Mathematical Models | Microsimulation | Child/Nutrition | Social Determinants | Policy/Regulation | Economics/Finance | Food/Agriculture | North America -
ArticlePublication 2017Cost-Effectiveness of a Policy Strategy to Decrease Sodium Intake: Global Analysis
The objective of this study was to assess the cost effectiveness of a government policy combining …
The objective of this study was to assess the cost effectiveness of a government policy combining targeted industry agreements and public education to reduce sodium intake in 183 countries worldwide. To account for heterogeneity in efficacy across countries, a range of scenarios were evaluated, including 10%, 30%, 0.5 g/day, and 1.5 g/day sodium reductions achieved over 10 years. Country specific costs of a sodium reduction policy were estimated using the WHO Noncommunicable Disease Costing Tool. Country…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Child/Nutrition | Social Determinants | Policy/Regulation | Food/Agriculture | Government/Law | Global -
ArticlePublication 2016Health, Financial and Distributional Consequences of Tobacco Excise Tax in Lebanon
This paper considers the financial and health effects, by socio-economic class, of increasing tobacco taxes …
This paper considers the financial and health effects, by socio-economic class, of increasing tobacco taxes in Lebanon, a middle-income country. Extended cost-effectiveness analysis (ECEA) methods are applied to quantify, across quintiles of socio-economic status, the health benefits gained, the additional tax revenues raised, and the net financial consequences for households from a 50% increase in the price of tobacco through excise taxes. The increase in tobacco tax is estimated to result in 65,000 premature deaths…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Costing Methods | Policy/Regulation | Middle East & North Africa